TrialClinIQ Secures Pre-Seed Funding to Accelerate AI-Driven Patient Recruitment in Clinical Trials

TrialClinIQ just pulled in $150K in Pre-Seed funding from Caduceus Capital Partners, stepped into the Caduceus LAUNCH accelerator, and quietly cracked open a $1.5M round. Houston stays underrated until it doesn’t, and this one is less about noise and more about pressure building in the pipes of clinical research.

The story starts where most platforms don’t. Dr. Jontel Pierce, MD, Founder & CEO, board-certified neurologist, clinical researcher, principal investigator, owner of MIND Neurology Clinic, and Clinical Assistant Professor at the University of Houston College of Medicine, wasn’t watching recruitment break from a dashboard. She was inside it. Clinics, trials, patients slipping through cracks that should not exist in a system this advanced on paper.

So TrialClinIQ leans into exactly that tension. AI-driven patient matching wired into EHR/EMR systems, secure APIs moving data instead of letting it rot, dashboards that actually track progress, and a patient portal that doesn’t feel like an afterthought. The focus lands on CNS trials and underrepresented populations, where complexity is high and visibility is usually low.

The company states its platform can reduce time-to-enrollment by 40%, lower costs, and improve diversity and retention. Those aren’t vanity metrics if they hold. That is operational gravity shifting. Trials don’t fail because the science is weak. They fail because the right patients never show up at the right time.

Caduceus Capital Partners doesn’t swing at random, and Caduceus LAUNCH is designed to put companies in rooms where distribution, data, and decision-makers intersect. StartUp Health’s backing adds another layer, while the HHS interoperability exposure hints at something bigger: this is not just about filling trials faster, it is about making patient data actually move with purpose.

The pattern is familiar if you know where to look. Founder sees inefficiency up close. Builds something that removes friction instead of decorating it. Gets early institutional signal. Starts threading into larger systems that have been slow to adapt.

TrialClinIQ reads like infrastructure disguised as a startup. Not loud, not bloated, just pointed at a constraint point the entire industry complains about and rarely fixes. The kind of company that doesn’t need to oversell because the problem already does the talking.